ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NFX Nuformix Plc

0.0525
0.00 (0.00%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.05P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 0.0525 6,586,003 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.05 0.055
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations -859k -0.0006 -0.83 745.14k
Last Trade Time Trade Type Trade Size Trade Price Currency
13:35:32 O 4,711,241 0.0526 GBX

Nuformix (NFX) Latest News

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
10/12/202416:49NUFORMIX September 2 Presentations - Massive Upside NFX563
18/5/202306:08Nuformix plc9,116
28/1/202115:43****NFX2021****1

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:35:340.054,711,2412,478.11O
08:47:310.05200,000105.40O
08:18:180.05100,00052.70O
08:05:050.051,574,762829.90O

Nuformix (NFX) Top Chat Posts

Top Posts
Posted at 13/12/2024 08:20 by Nuformix Daily Update
Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.05p.
Nuformix currently has 1,419,309,368 shares in issue. The market capitalisation of Nuformix is £709,655.
Nuformix has a price to earnings ratio (PE ratio) of -0.83.
This morning NFX shares opened at -
Posted at 29/10/2024 17:34 by for fx sake
There are 819m shares in issue right now worth about 0.055p per share. There will shortly be around 1.4bn in issue.1.4bn shares at 2p values this company at 28m. We are currently worth 0.5m.Who is going to £28m in 6 months to buy a company they could buy for less than 1m now?
Posted at 25/9/2024 13:04 by socionomics
Do the opposite of what Sheedy does and you won't go far wrong. BT/VOD/ITV/OPTI/SBTX....the list goes on.

He has only ever been bullish on NFX (at 6p. WTF! The guy is clueless. The laughing stock of ADVFN.
Posted at 05/9/2024 13:16 by jotoha2
The idle chatter was just before the last fund raise , so no substance behind it , question is has Dan something to sell , he needs a White Knight with lots of cash! A low price takeout and a couple of years with a decent salary will probably be the best for him , it looks like the end quite soon.
Posted at 08/8/2024 11:54 by leadersoffice
A lot of f e c k I n g about with the share price. Are er ever going to get back to 1p and over ??
Posted at 06/8/2024 11:11 by socionomics
This is NFX. Have you been drinking?
Posted at 06/8/2024 11:05 by citys2874
CGH may do 400 percent today worth buying today. This and NFX having a great morning
Posted at 31/7/2024 10:44 by washingmachine
If he pulls it off
NFX will 10 bag minimum
Excellent risk / reward here
Posted at 15/7/2024 17:55 by nobbygnome
Skull driller is one of his many avatars. He claims to be a guru but his record of shorts and longs is truly shocking….SYME and NFX are just two of his disasters!
Posted at 18/6/2024 15:43 by for fx sake
You might need to recalculate that. 10m divided by 819.31m shares is not 12p per share
Posted at 14/12/2021 17:53 by sentiment riles
Lanstead Investment – Q&A
Q. Why did Nuformix choose the Sharing Agreements with Lanstead?
A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price
performance over 20 months and the funding supports Nuformix’s activities over that period. We
see a number of positive catalysts for Nuformix over the coming months, in particular as we make
NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be
positive for the share price as these are announced.
Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix
share price from month-to-month?
A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p
per share. The number of shares issued to Lanstead is fixed and does not change. However, the
amount from Lanstead due to the Company under the sharing agreements is adjustable upwards
or downwards at each of the 20 monthly settlements that follow. For example; the approximate
amount in any particular month will be 10% more than £82,500 if the share price is 10% higher
than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower
than the BMP.
Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than
going higher than 2.0p?
A: No. Lanstead makes more money the higher the share price is. Through the sharing
agreements Lanstead shares some, but not all, of the upside when the share price appreciates
with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby
benefitting all shareholders including Lanstead.
If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will
receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65
million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company
will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65
million).
The projected outcome for Nuformix is contractually clear and the value of Lanstead’s
investment is greater if the company’s share price is higher.
It is important to note that Lanstead participates in the majority, but not all of the upside in any
future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as
the share price rises and does not derive any advantage from a decline in the share price.
Q: Can Lanstead trade its Nuformix shares?
A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its
investee companies. Like any institutional investor Lanstead only invests in companies where it
can see strong potential for share price appreciation.
Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose
movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead
has an uncapped commitment through the sharing agreements to remit amounts each month to
Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along
the way (like any shareholder) and cover its downside risk on the investment (just like any
shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant
on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over
the 20 months of the sharing agreements should the Nuformix shares appreciate
Nuformix share price data is direct from the London Stock Exchange

Nuformix Frequently Asked Questions (FAQ)

What is the current Nuformix share price?
The current share price of Nuformix is 0.0525p.
How many Nuformix shares are in issue?
Nuformix has 1,419,309,368 shares in issue.
What is the market cap of Nuformix?
The market capitalisation of Nuformix is GBP 745,137.42 .
What is the 1 year trading range for Nuformix share price?
Nuformix has traded in the range of 0.04p to 0.44p during the past year.
What is the PE ratio of Nuformix?
The price to earnings ratio of Nuformix is -0.83.
What is the reporting currency for Nuformix?
Nuformix reports financial results in GBP.
What is the latest annual profit for Nuformix?
The latest annual profit of Nuformix is GBP -859k.
What is the registered address of Nuformix?
The registered address for Nuformix is 6TH FLOOR, 60 GRACECHURCH STREET, LONDON, EC3V 0HR.
What is the Nuformix website address?
The website address for Nuformix is www.nuformix.com.
Which industry sector does Nuformix operate in?
Nuformix operates in the PHARMACEUTICAL PREPARATIONS sector.

Your Recent History

Delayed Upgrade Clock